This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (11)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Bacterial Infections  • Immunization  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Mike Mitka

JAMA. 2005;293:1433-1434.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The recent licensing of a new meningococcal conjugate vaccine has prompted government officials to expand recommended immunization practices. The new vaccine is expected to drastically reduce the prevalence of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135, which make up the majority of cases in the United States.

A new meningoccal vaccine is expected to markedly reduce the prevalence of invasive disease caused by Neisseria meningitidis. (Photo credit: www.sciencesource.com)

The Advisory Committee on Immunization Practices to the Centers for Disease Control and Prevention (CDC) recommended on February 10 that children aged 11 and 12 years, teens entering high school, and college freshman living in dormitories receive meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (Menactra). This vaccine, manufactured by Sanofi Pasteur (Swiftwater, Pa), received US Food and Drug Administration approval on January 14, 2005.

IMPROVED IMMUNITY

Menactra promises to . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Quest for a broad-range vaccine against Neisseria meningitidis serogroup B: implications of genetic variations of the surface-exposed proteins
de Filippis
J Med Microbiol 2009;58:1127-1132.
ABSTRACT | FULL TEXT  

Neisseria meningitidis antigen NMB0088: sequence variability, protein topology and vaccine potential
Sardinas et al.
J Med Microbiol 2009;58:196-208.
ABSTRACT | FULL TEXT  

Update on Prevention of Meningococcal Disease: Focus on Tetravalent Meningococcal Conjugate Vaccine
Mehlhorn et al.
The Annals of Pharmacotherapy 2006;40:666-673.
ABSTRACT | FULL TEXT